MC1R variants may also impact treatment outcomes: metastatic melanoma patients with concurrent BRAF V600 mutations and MC1R variants experienced lower response rates and shorter PFS on BRAF inhibitor therapy [89]. The gene discussed is MC1R; the disease is metastatic melanoma.